Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Patricia McClerklin

Dermatology Orangeburg, SC Medical Doctor

NPI 1154428100 CMS profile 189023

1585 Carolina Ave, Orangeburg, SC 29115

Open in the dashboard

General payments

$32,677

1,382 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Patricia McClerklin of Orangeburg, SC is reported in the CMS Open Payments database as having received $32,677 across 1,382 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,968 166
2024 General $4,362 201
2023 General $4,593 236
2022 General $4,161 209
2021 General $3,313 190
2020 General $2,164 89
2019 General $10,116 291

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Patricia McClerklin
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Patricia McClerklin were reported at $3,968. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Patricia McClerklin Dermatology median Middle half National median
2019 $10,116 $454 $129–$1,240 $163
2020 $2,164 $235 $81–$756 $114
2021 $3,313 $377 $108–$1,108 $132
2022 $4,161 $514 $143–$1,391 $149
2023 $4,593 $607 $159–$1,674 $160
2024 $4,362 $751 $204–$1,903 $164
2025 $3,968 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $6,439 67 payments
  2. Novartis Pharmaceuticals Corporation $3,130 103 payments
  3. AbbVie, Inc. $2,843 162 payments
  4. Janssen Biotech, Inc. $1,876 135 payments
  5. Genzyme Corporation $1,695 76 payments
  6. UCB, Inc. $1,636 75 payments
  7. E.R. Squibb & Sons, L.L.C. $1,174 64 payments
  8. Medimetriks Pharmaceuticals, Inc. $1,039 24 payments
  9. Amgen Inc. $1,026 48 payments
  10. LEO Pharma Inc. $999 44 payments
  11. Other $10,821 584 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $26,754 1,364 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,250 2 payments
  3. Education $673 16 payments
Products named General payments · program years 2019–2025
  1. EUCRISA $6,015 53 payments
  2. DUPIXENT $2,525 112 payments
  3. TREMFYA $1,740 111 payments
  4. COSENTYX Immunology $1,670 44 payments
  5. SOTYKTU $1,174 64 payments
  6. RINVOQ $1,151 58 payments
  7. COSENTYX Dermatology $1,128 34 payments
  8. Bimzelx $1,021 42 payments
  9. Otezla $987 46 payments
  10. NUZYRA $976 63 payments
  11. Other $18,725 988 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

2,166

Median for Dermatology: 534

Drug cost

$2,039,008

Median for Dermatology: $67,151

Branded share of claims

18.1%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 46 $388,245
Bimzelx Autoinjector Bimekizumab-Bkzx Brand 24 $355,969
Dupixent Pen Dupilumab Brand 90 $339,483
Skyrizi Pen Risankizumab-Rzaa Brand 16 $325,497
Tremfya Guselkumab Brand 13 $176,563
Cosentyx Sensoready (2 Pens) Secukinumab Brand 19 $140,443
Taltz Autoinjector Ixekizumab Brand 18 $116,599
Rinvoq Upadacitinib Brand 13 $84,033
Otezla Apremilast Brand 13 $62,949
Clobetasol Propionate Generic 262 $8,164

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$32,347

Of which drugs: $219

Medicare patients

167

Average age 68

Services billed

799

121 women, 46 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 44%
Diabetes 38%
Chronic kidney disease 28%
Ischemic heart disease 21%
Depression 20%
Heart failure 16%
COPD 11%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 28 333 $219

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 33 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SOTYKTU
$418 — —
DUPIXENT
$408 90 —
TREMFYA
$383 13 —
NUZYRA
$365 — —
RINVOQ
$361 13 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 33 with Patron

Records

1,382 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record